The Budget Impact Of Introducing A PD-L1 Assay To Select Patients With Metastatic Nsclc Who Are Potential Candidates For Treatment With Immune Checkpoint Inhibitors
Abstract
Authors
B Sheppard M Ahlsten D Paolini J Xenakis W Zhang